"A phase III, Multicenter, Randomized, Double-blind Study to Assess Efficacy and Safety of Two Doses of Crizanlizumab versus placebo, with or without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Vaso-Occlusive Crises (STAND)"
2022-06-28
عنوان الدراسة
"A phase III, Multicenter, Randomized, Double-blind Study to Assess Efficacy and Safety of Two Doses of Crizanlizumab versus placebo, with or without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Vaso-Occlusive Crises (STAND)"
داعم الدراسة
Novartis
دواء الدراسة
Crizanlizumab
رقم بروتوكول الدراسة
CSEG101A2301
حالة الدراسة
Ongoing
موقع الدراسة
King Fahad Medical City (Riyadh)
مرحلة الدراسة
3
评论与建议
如对政府服务有任何咨询或意见,请填写所需信息。